Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 20/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454469 | 0.91 | CCR1 (0.62) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4449328 | 0.89 | CCR1 (0.64) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4452507 | 0.88 | CCR1 (0.71) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4454993 | 0.87 | CCR1 (0.70) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4458768 | 0.86 | CCR1 (0.69) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4450699 | 0.85 | CCR1 (0.66) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4458551 | 0.85 | CCR1 (0.68) | CCR1CYP2C19KCNH2 | |
| SCHEMBL13761265 | 0.85 | CCR1 (0.67) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4452308 | 0.81 | CCR1 (0.62) | CCR1CYP2C19KCNH2 | |
| SCHEMBL5313050 | 0.80 | CCR1 (0.43) | CCR1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576218-B2 | 4-phenylpiperdine-pyrazole CCR1 antagonists | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576218-B2 | 4-phenylpiperdine-pyrazole CCR1 antagonists | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070088036-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088036-A1 | Piperidine derivatives and methods of use | CCR1, CCR3, CCR4 | CCR1 1/4885CYP2C19 3474/4885KCNH2 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.